GSK Reported Strong Earnings, So I Reiterate My Strong Buy
GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...
pharmaphorum2d
GSK asthma hope depemokimab works in second indication
GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...
pharmaphorum2d
ERS: GSK reveals data behind new asthma hope depemokimab
GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS ...
FiercePharma6d
With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
EconoTimes6d
GSK Raises 2031 Sales Forecast to £40B Amid Strong Specialty Medicine Growth
GSK (LON:GSK) has raised its long-term revenue outlook, now expecting sales to exceed 40 billion by 2031, up from 38 billion.
GSK lifts long-term sales outlook on strong Specialty Medicines growth
GSK’s global performance showed strength across key markets. Sales in the United States reached £16.4 billion, up 6% at ...
Nasdaq6d
GSK Beats on Q4 Earnings & Sales, Stock Up on Raised Long-Term Outlook
This year, GSK expects to launch five new products/line extensions, including Blenrep (relaunch in multiple myeloma), depemokimab (for severe asthma and chronic rhinosinusitis with nasal polyps ...